Latest news with #CraigHallum
Yahoo
2 days ago
- Business
- Yahoo
Craig-Hallum Lifts PT on Enovix (ENVX) Stock
Enovix Corporation (NASDAQ:ENVX) is one of the Best Performing EV Stocks So Far in 2025. Craig-Hallum lifted the price objective on the company's stock to $15 from $12, while keeping a 'Buy' rating, as reported by The Fly. This comes after Enovix Corporation (NASDAQ:ENVX) released its preliminary June results with revenue and adjusted EBITDA surpassing the midpoint of previous guidance. As per the firm, the outperformance was mainly due to the company's Korean divisions. Furthermore, the company launched its AI-1, an artificial intelligence-focused battery for next-gen smartphone applications, and has started sampling. A close-up of a battery cell being assembled with intricate precision. As per the preliminary Q2 2025 results, Enovix Corporation (NASDAQ:ENVX) saw revenue of $7.5 million, while the adjusted EBITDA loss narrowed to $21.4 million. The company highlighted that this was its 5th straight quarter exceeding the midpoint of guidance for both revenue and adjusted EBITDA. Enovix Corporation (NASDAQ:ENVX) announced the acquisition of battery cell manufacturing assets from SolarEdge, which is located in South Korea. The acquisition is expected to expand the company's manufacturing footprint and help position Enovix Corporation (NASDAQ:ENVX) to cater to growing demand in the broader defense industry. Massif Capital, an investment management company, released its Q4 2024 investor letter. Here is what the fund said: 'Our most volatile position remains Enovix Corporation (NASDAQ:ENVX), and we admit to being miffed by its continued volatility. At one point, it made sense as it was a story stock, but at this point, the stock has advanced well beyond being a story. Despite the progress the firm is making operationally, the stock has historically annualized volatility over rolling 100-day periods of nearly 100%. Last year, the stock moved more than 30% from local lows to local highs four times; it also had drawn downs from local highs to local lows of more than 35% three times. The short interest in the stock also remains incredibly high at more than 30% of the stock's float. Enovix Corporation (NASDAQ:ENVX) is engaged in designing, developing, and manufacturing lithium-ion battery cells. The company serves wearables and IoT, smartphones, computing, EVs, and original equipment manufacturers. While we acknowledge the potential of ENVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-07-2025
- Business
- Yahoo
Craig-Hallum Remains Bullish on Photronics (PLAB)
Photronics, Inc. (NASDAQ:PLAB) is one of the best cheap stocks with huge upside potential. In a report released on July 1, Christian Schwab from Craig-Hallum maintained a Buy rating on Photronics, Inc. (NASDAQ:PLAB). An engineer manipulating a complex circuit board that will be used in flat panel displays. The company also recently announced a transition in leadership, with Dr. Frank Lee stepping down from his role as the company's CEO while retaining his position as Chairman and President of Photronics' PDMC subsidiary in Taiwan. Mr. George Macricostas took the role of the new CEO of Photronics, Inc. (NASDAQ:PLAB) while remaining Chairman of the Board. The company reported $211.0 million in revenue in fiscal Q2 2025, down 3% year-over-year and 1% sequentially. Photronics, Inc. (NASDAQ:PLAB) expects revenue for fiscal Q3 to be in the $200 million and $208 million range, and net income attributable to shareholders to be between $0.35 and $0.41 per diluted share. Photronics, Inc. (NASDAQ:PLAB) provides photomasks, which are glass or quartz plates with microscopic images of electronic circuits and are used for the fabrication of flat-panel displays and integrated circuits. While we acknowledge the potential of PLAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Globe and Mail
12-07-2025
- Business
- Globe and Mail
Credo Technology Group Holding Ltd (CRDO) Receives a Rating Update from a Top Analyst
In a report released today, Richard Shannon from Craig-Hallum maintained a Buy rating on Credo Technology Group Holding Ltd. The company's shares closed yesterday at $97.29. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Shannon is a top 100 analyst with an average return of 35.4% and a 54.29% success rate. Shannon covers the Technology sector, focusing on stocks such as IonQ, Navitas Semiconductor, and AXT. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Credo Technology Group Holding Ltd with a $92.55 average price target, representing a -4.87% downside. In a report released on July 9, Bank of America Securities also assigned a Buy rating to the stock with a $120.00 price target. Based on Credo Technology Group Holding Ltd's latest earnings release for the quarter ending May 3, the company reported a quarterly revenue of $170.03 million and a net profit of $36.59 million. In comparison, last year the company earned a revenue of $60.78 million and had a GAAP net loss of $10.48 million Based on the recent corporate insider activity of 150 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRDO in relation to earlier this year. Last month, Lip Bu Tan, a Director at CRDO sold 92,248.00 shares for a total of $8,403,136.08.
Yahoo
07-07-2025
- Business
- Yahoo
Craig-Hallum Reiterates a Buy Rating on Clover Health Investments (CLOV), Sets a $6 PT
Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the 13 Stocks Under $5 With High Upside Potential. In a report released on May 7, Matt Hewitt from Craig-Hallum reiterated a Buy rating on Clover Health Investments, Corp. (NASDAQ:CLOV) with a price target of $6.00. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. The company reported notable fiscal Q1 2025 results that support this optimistic outlook, with Medicare Advantage membership for the quarter reaching 103,418, representing a 30% year-over-year increase. Total revenue for fiscal Q1 2025 rose 33% year-over-year to $462 million, while adjusted EBITDA reached $26 million, reflecting a significant 279% year-over-year rise. Adjusted net income also grew 322% year-over-year to $25 million. In addition, Clover Health Investments, Corp. (NASDAQ:CLOV) reported a GAAP net loss of $1 million, compared to $19 million a year ago, suggesting a considerable improvement in its operations. Clover Health Investments, Corp. (NASDAQ:CLOV) is a physician enablement technology company that offers Medicare Advantage plans in the United States. It offers PPO and HMO Medicare Advantage plans in several US states. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
03-07-2025
- Business
- Yahoo
Craig-Hallum Trims Simulations (SLP) Price Target, Maintaining a Buy Rating
Simulations Plus, Inc. (NASDAQ:SLP) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation software for pharmaceutical research, saw its price target lowered by Craig-Hallum to $36 from $45 following a cautious Q3 pre-release and a downward revision of its fiscal year 2025 guidance. Despite maintaining a Buy rating, the firm highlighted growing macroeconomic headwinds that are weighing on the company's services segment. Clients have reportedly been slow to initiate new contracts, delay clinical trials, and hold off on major spending decisions—a trend that's been broadly felt across the healthcare landscape. A close-up view of a scientist's hand pressing keys on a laptop as another looks closely at a 3-D model on a large monitor. However, Simulations Plus' core software segment remains resilient. Known for its predictive modeling platforms used in drug discovery and development, the company plays a key role in advancing New Approach Methodologies (NAMs), which aim to modernize and reduce reliance on traditional clinical trials. These technologies, essential in streamlining the drug development process, are gaining broader acceptance across regulators and pharmaceutical companies, solidifying Simulations Plus' role in a rapidly evolving healthcare ecosystem. Craig-Hallum sees long-term potential in this structural shift. While near-term disruptions may cloud visibility, the firm notes that Simulations Plus continues to operate in a growing, innovation-driven market. For investors looking to align with the digital transformation of drug development, the company represents a compelling opportunity rooted in both regulatory trends and scientific advancement. While we acknowledge the potential of SLP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLP and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio
